Immune hierarchy among HIV-1 CD8+ T cell epitopes delivered by dendritic cells depends on MHC-I binding irrespective of mode of loading and immunization in HLA-A*0201 mice

APMIS

Volumn 117, Issue 11, 2009, Pages 849-855

  Kloverpris, Henrik N ^a   Karlsson, Ingrid ^a   Thorn, Mette ^a   Buus, Søren ^b   Fomsgaard, Anders ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

CTL epitopes; Dendritic cells; HLA A*0201; Immunodominance

Indexed keywords

EPITOPE; HLA A ANTIGEN; PEPTIDE;

ANIMAL EXPERIMENT; ARTICLE; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

AIDS VACCINES; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, T-LYMPHOCYTE; FLOW CYTOMETRY; HIV INFECTIONS; HIV-1; HLA-A ANTIGENS; INTERFERON-GAMMA; MICE; MICE, TRANSGENIC; T-LYMPHOCYTES, CYTOTOXIC;

EID: 70350341006     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2009.02544.x     Document Type: Article

References (23)

1. Phillips RE, Rowland-Jones S, Nixon DF, Gotch FM, Edwards JP, Ogunlesi AO, et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 1991 354 : 453 459.
2. Estcourt MJ, McMichael AJ, Hanke T. DNA vaccines against human immunodeficiency virus type 1. Immunol Rev 2004 199 : 144 155.
3. Ide F, Nakamura T, Tomizawa M, Kawana-Tachikawa A, Odawara T, Hosoya N, et al. Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial. J Med Virol 2006 78 : 711 718.
4. Kundu SK, Engleman E, Benike C, Shapero MH, Dupuis M, van Schooten WC, et al. A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients. AIDS Res Hum Retroviruses 1998 14 : 551 560.
5. + T cell responses during chronic untreated HIV-1 infection by immunization with subdominant CTL epitopes. AIDS 2009 23 : 1329 1340.
6. Durier C, Launay O, Meiffredy V, Saidi Y, Salmon D, Levy Y, et al. Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults. AIDS 2006 20 : 1039 1049.
7. Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 1999 17 : 51 88.
8. Tenzer S, Wee E, Burgevin A, Stewart-Jones G, Friis L, Lamberth K, et al. Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nat Immunol 2009 6 : 636 646.
9. Sette A, Sidney J, del Guercio MF, Southwood S, Ruppert J, Dahlberg C, et al. Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. Mol Immunol 1994 31 : 813 822.
10. Kedl RM, Rees WA, Hildeman DA, Schaefer B, Mitchell T, Kappler J, et al. T cells compete for access to antigen-bearing antigen-presenting cells. J Exp Med 2000 192 : 1105 1113.
11. Wolpert EZ, Grufman P, Sandberg JK, Tegnesjo A, Karre K. Immunodominance in the CTL response against minor histocompatibility antigens: interference between responding T cells, rather than with presentation of epitopes. J Immunol 1998 161 : 4499 4505.
12. Corbet S, Nielsen HV, Vinner L, Lauemoller S, Therrien D, Tang S, et al. Optimization and immune recognition of multiple novel conserved HLA-A2, human immunodeficiency virus type 1-specific CTL epitopes. J Gen Virol 2003 84 : 2409 2421.
13. + T-lymphocyte cross-recognition may explain the immune reaction in infected individuals. APMIS 2007 115 : 757 768.
14. Sylvester-Hvid C, Kristensen N, Blicher T, Ferre H, Lauemoller SL, Wolf XA, et al. Establishment of a quantitative ELISA capable of determining peptide-MHC class I interaction. Tissue Antigens 2002 59 : 251 258.
15. Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, Maewal A, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994 1 : 751 761.
16. Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, Perarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 1997 185 : 2043 2051.
17. Busch DH, Pamer EG. T cell affinity maturation by selective expansion during infection. J Exp Med 1999 189 : 701 710.
18. Sette A, Vitiello A, Reherman B, Fowler P, Nayersina R, Kast WM, et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 1994 153 : 5586 5592.
19. van der Burg SH, Visseren MJ, Brandt RM, Kast WM, Melief CJ. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J Immunol 1996 156 : 3308 3314.
20. Grufman P, Sandberg JK, Wolpert EZ, Karre K. Immunization with dendritic cells breaks immunodominance in CTL responses against minor histocompatibility and synthetic peptide antigens. J Leukoc Biol 1999 66 : 268 271.
21. Lanzavecchia A. Lack of fair play in the T cell response. Nat Immunol 2002 3 : 9 10.
22. Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 2001 106 : 263 266.
23. Leslie A, Price DA, Mkhize P, Bishop K, Rathod A, Day C, et al. Differential selection pressure exerted on HIV by CTL targeting identical epitopes but restricted by distinct HLA alleles from the same HLA supertype. J Immunol 2006 177 : 4699 4708.